ArticleMolecular cancer therapeutics2019

Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties.

Liangxian Cao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.